Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 17 2025
0mins
Should l Buy ?
Source: Globenewswire
Elicio Therapeutics Event Announcement: Elicio Therapeutics will host a virtual key opinion leader event on June 25, 2025, to discuss the treatment landscape for mutant-KRAS driven pancreatic cancer and present insights from leading experts in the field.
ELI-002 Vaccine Development: The company's lead product candidate, ELI-002, is an AMP-powered therapeutic vaccine currently in a Phase 2 trial aimed at treating mKRAS-driven pancreatic ductal adenocarcinoma, with interim analysis results expected in Q3 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
